Want to see SVRA full AI Analyst Report?
Top Page
Savara
(NASDAQ:SVRA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.50
▼(-4.84% Downside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by weak financial performance—no revenue, widening losses, and increasing cash burn that elevates funding/dilution risk. Technicals are broadly neutral and do not offset the fundamentals, while valuation is difficult to support with a negative P/E. Corporate actions increasing authorized shares further reinforce dilution risk.
Positive Factors
Focused rare-disease pipeline
Savara’s clinical-stage focus on inhaled molgramostim for aPAP reflects a targeted strategy addressing a clearly defined rare respiratory indication. A concentrated pipeline in an orphan disease can yield durable regulatory exclusivities, streamlined development focus, and clearer commercialization pathways if approved.
Negative Factors
No revenue and widening losses
Savara remains pre-revenue with materially widening net losses over multiple years, indicating persistent negative operating leverage. Without product revenues, continued R&D spending will keep losses elevated and pressure capital resources unless development milestones or approvals materially change the revenue outlook.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused rare-disease pipeline
Savara’s clinical-stage focus on inhaled molgramostim for aPAP reflects a targeted strategy addressing a clearly defined rare respiratory indication. A concentrated pipeline in an orphan disease can yield durable regulatory exclusivities, streamlined development focus, and clearer commercialization pathways if approved.
Read all positive factors
Savara (SVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.13B
Dividend YieldN/A
Average Volume (3M)1.86M
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth-12.97%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,579,429
30 Day Avg. Volume1,860,238
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Savara Business Overview & Revenue Model
Company Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimula...
How the Company Makes Money
Savara does not have a traditional commercial revenue model because it does not currently sell approved products. As a clinical-stage biotechnology company, its operations are primarily funded through external financing (e.g., issuing equity and, ...
Savara Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -21.08M | -245.00K | -78.03M | -44.26M | -27.88M | -28.99M |
| EBITDA | -129.27M | -118.59M | -102.27M | -59.13M | -38.01M | -40.50M |
| Net Income | -129.48M | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M |
Balance Sheet | ||||||
| Total Assets | 221.65M | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M |
| Cash, Cash Equivalents and Short-Term Investments | 202.77M | 235.70M | 196.33M | 162.32M | 125.88M | 161.17M |
| Total Debt | 30.11M | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M |
| Total Liabilities | 45.61M | 50.30M | 41.43M | 37.19M | 32.00M | 32.10M |
| Stockholders Equity | 176.04M | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M |
Cash Flow | ||||||
| Free Cash Flow | -106.97M | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M |
| Operating Cash Flow | -106.89M | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M |
| Investing Cash Flow | -8.99M | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M |
| Financing Cash Flow | 135.29M | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M |
Savara Technical Analysis
Neutral
5.78
Price Trends
5.46
Positive
5.45
Positive
5.31
Positive
Market Momentum
0.07
Positive
43.09
Neutral
12.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Neutral. The current price of 5.78 is below the 20-day moving average (MA) of 5.93, above the 50-day MA of 5.46, and above the 200-day MA of 5.31, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of 12.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SVRA.
Savara Risk Analysis
Savara disclosed 37 risk factors in its most recent earnings report. Savara reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Savara Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $750.07M | 2.02 | 147.03% | ― | 47.61% | 854.73% | |
56 Neutral | $1.82B | -9.99 | -35.89% | ― | ― | -63.41% | |
52 Neutral | $1.91B | -64.63 | 31.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.72B | -68.24 | 442.91% | ― | 107.73% | 82.33% | |
48 Neutral | $1.00B | -5.68 | -45.95% | ― | ― | -3.83% | |
44 Neutral | $1.13B | -9.86 | -87.19% | ― | ― | -12.97% |
* Healthcare Sector Average
SVRA
Savara
5.52
3.23
141.05%
RIGL
Rigel
40.54
20.95
106.94%
ANAB
AnaptysBio
58.00
40.56
232.49%
OLMA
Olema Pharmaceuticals
11.47
6.88
149.89%
NBTX
Nanobiotix
37.79
32.68
639.53%
BCAX
Bicara Therapeutics Inc.
27.76
16.52
146.98%
Savara Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Savara Expands Share Capital and Updates Executive Leadership
Positive
Jun 8, 2026
On June 4, 2026, Savara’s stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the pool of shares available for equity awards by 18,900,000, and also doubled the company’s authorized common stock from 300,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.